Efficacy and safety of plasma hemodiafiltration (PHDF) in pediatric patients with multiple organ dysfunction syndrome with shock and DIC: a preliminary study

Table 2 Changes in clinical scores, vital signs, and laboratory findings

Variables		Day 0	Day 1	Day 3	Day 5	Day 7
PELOD-2 score		20 [15-22]	16 [9.5-18]	13 [9.0-18]	10* [9.0-14]	9.0* [8.0-14]
VIS score		15 [13-35]	10 [6.0-17]	9.0* [6.0-15]	4.5 [2.5-17]	3.0* [2.0-7.4]
LMHW score		10 [8.0-13]	7.0* [5.5-8.5]	7.0* [5.0-8.5]	7.0* [4.0-7.0]	6.0* [3.0-7.0]
MAP		1.0	1.5* [1.1-1.8]	1.2 [1.0-1.8]	1.8* [1.5-2.0]	1.6* [1.4-2.1]
CVP		1.0	1.1 [0.8-1.8]	1.0 [0.6-1.5]	0.7* [0.4-1.1]	0.6* [0.4-0.9]
Urine volume	(mL/kg/h)	0.3 [0.2-0.5]	0.1 [0.1-1.0]	0.3 [0.1-0.4]	0.2 [0.1-0.7]	1.1 [0.1-1.8]
Water balance	(%)	16 [14-24]	3.7* [1.8-11]	4.1* [1.6-8.8]	3.1* [7.2-1.2]	1.6* [3.3-0.5]
TP	(g/dL)	4.5 [3.5-4.8]	7.4* [6.8-8.1]	6.9* [5.9-8.2]	7.2* [6.4-7.8]	7.3* [5.9-7.6]
Lactate	(mmol/L)	7.3 [4.1-16]	5.3 [3.6-10]	4.1 [2.6-8.2]	2.8* [1.5-4.8]	1.8* [1.4-3.7]
PLT	(×10⁴)	4.6 [3.1-6.8]	9.9* [6.6-16]	11.7* [5.6-20]	6.5 [5.6-114]	12* [9.3-21]
TAT	(ng/mL)	38.1 [24.4-450]	89.6 [13.6-154]	28.4 [10.8-77.0]	19.4 [9.7-37.0]	9.5 [5.6-20.0]
PIC	(pg/mL)	3.6 [0.85-11.0]	3.1 [0.58-6.2]	8.8 [1.40-11.2]	6.0 [2.5-16.6]	4.9 [3.0-8.0]
PAI-1	(ng/mL)	379 [174-1240]	531 [372-848]	322 [102-616]	130 [27.7-173]	34.2 [23.7-460]

Data are presented as median [interquartile range]. MAP and CVP are expressed as a ratio to the value at day 0
PELOD-2 Pediatric Logistic Organ Dysfunction-2, VIS vasoactive inotropic score, JMHW Japanese Ministry of Health and Welfare, MAP mean arterial pressure, CVP central venous pressure, TP total protein, PLT platelet count, TAT thrombin–antithrombin complex, PIC plasmin α2–plasmin inhibitor complex, PAI-1 plasminogen activator inhibitor-1
*p < 0.05 compared with before the treatment (day 0) by Kruskal–Wallis test and post hoc Steel tests

ISSN: 2059-1381